Clinical Trial Update: A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

This document provides a status update on a Phase 2 clinical trial of ADI-PEG 20 for malignant pleural mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Barts & The London NHS Trust | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: UNKNOWN